|
|
Volumn 13, Issue 8, 2014, Pages 571-572
|
|
Antithrombotic drugs market
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALTEPLASE;
ANTICOAGULANT AGENT;
APIXABAN;
BETRIXABAN;
BLOOD CLOTTING FACTOR 10A INHIBITOR;
CANGRELOR;
CLOPIDOGREL;
DABIGATRAN ETEXILATE;
DESMOTEPLASE;
EDOXABAN;
ENOXAPARIN;
EP 217609;
LIXIANA;
PEGNIVACOGIN;
PRASUGREL;
RIVAROXABAN;
TEARXABAN;
TECARFARIN;
THR 18;
TICAGRELOR;
UNCLASSIFIED DRUG;
VORAPAXAR;
WARFARIN;
ZONTIVITY;
ACUTE CORONARY SYNDROME;
ANTICOAGULATION;
ARTICLE;
BRAIN ISCHEMIA;
CEREBROVASCULAR ACCIDENT;
DEEP VEIN THROMBOSIS;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG SAFETY;
DRUG TOLERABILITY;
HEART INFARCTION;
HIGH RISK PATIENT;
HUMAN;
LUNG EMBOLISM;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RISK REDUCTION;
ANTICOAGULANTS;
CARDIOVASCULAR DISEASES;
DRUG DISCOVERY;
DRUG INDUSTRY;
FIBRINOLYTIC AGENTS;
HUMANS;
PLATELET AGGREGATION INHIBITORS;
|
|
EID: 84905961257
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4365 Document Type: Article |
|
Times cited : (26)
|
|
References (1)
|
